{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A PHASE 1B\/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH ATEZOLIZUMAB WITH OR\nWITHOUT CARBOPLATIN AS FIRST-LINE\nINDUCTION OR MAINTENANCE, IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1b-2-multicenter-open-label-study-of-ifinatamab-deruxtecan-i-dxd-a-b7-h3-antibody-drug-conjugate-adc-in-combination-with-atezolizumab-with-orwithout-carboplatin-as-first-lineinductio\/#breadcrumbitem"}]}